U.S. Liquid Biopsy Market, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

U.S. Liquid Biopsy Market Size

• The U.S. liquid biopsy market size was valued at USD 1.09 billion in 2024 and is expected to reach USD 3.59 billion by 2032, at a CAGR of 16.7% during the forecast period
• The liquid biopsy market is rapidly expanding due to its non-invasive nature, enabling early cancer detection, monitoring treatment response, and recurrence prediction is driving market penetration globally
• Furthermore, the market is expected to grow due to the Growing adoption in oncology, coupled with advancements in next-generation sequencing (NGS)

U.S. Liquid Biopsy Market Analysis

• Rising cancer prevalence, aging populations, and demand for personalized medicine, are key driving factors expected to propel the growth of the U.S. liquid biopsy market
• Key factors such as the Technological innovations, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosome-based assays, are broadening clinical applications are driving the growth of the U.S. liquid biopsy market
• In 2025, the consumables & accessories segment is expected to dominate the market with a market share of 50.95%. due to its high demand for routine testing, continuous replacement requirements, and essential role in ensuring accurate and reliable diagnostic results. The segment benefits from recurring purchases, widespread use in laboratories and hospitals, and growing adoption of advanced liquid biopsy technologies across clinical applications

Report Scope and U.S. Liquid Biopsy Market Segmentation

U.S. Liquid Biopsy Market Trends

Rising Adoption of Non-Invasive Diagnostics for Precision Medicine

• Liquid biopsies provide a non-invasive alternative to tissue biopsies, minimizing patient risk while enabling real-time monitoring of tumor evolution, treatment response, and minimal residual disease detection
• These tests are highly valuable for detecting circulating tumor DNA, exosomes, and other biomarkers, offering faster, safer, and more comprehensive diagnostic insights compared to conventional biopsy methods
• Expanding applications in early cancer detection, therapy selection, and recurrence monitoring are driving adoption across oncology, supported by advances in next-generation sequencing, PCR, and multi-omics platforms
• The shift toward precision medicine and personalized treatment strategies reinforces the demand for liquid biopsy, as it supports tailored therapies, enhances patient outcomes, and reduces the need for invasive procedures

U.S. Liquid Biopsy Market Dynamics

Driver

Rising Cancer Incidence Globally

• Cancer is the second major cause of death in the world and is a major worldwide public health problem. Early detection and appropriate therapy are crucial for cancer patients to enhance their prognosis and enhance their chances of survival
• As tumors are sometimes hard to detect early, it is difficult to use tissue biopsies to accurately detect tumors at an early stage in the diseases. Compared with tissue biopsy, liquid biopsy has many advantages in the diagnosis and treatment of various types of cancer, including non-invasive, quickly and so on
• Currently, the application of liquid biopsy in tumor detection has received widely attention. It is now undergoing rapid progress, and it holds significant potential for future applications
  • For Instance, In May 2025 National Cancer Institute estimated that 2,041,910 new cases of cancer will be diagnosed in the U.S. and 618,120 people will die from the disease. The rate of new cases of cancer (cancer incidence) is 445.8 per 100,000 men and women per year (based on 2018–2022 cases). The most common cancers (listed in descending order according to estimated new cases in 2025) are breast cancer, prostate cancer, lung and bronchus cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, kidney and renal pelvis cancer, non-Hodgkin lymphoma, uterine corpus cancer, pancreatic cancer, leukemia, thyroid cancer, and liver and intrahepatic bile duct cancer

Restraint/Challenge

High Cost of Advanced Liquid Biopsy Technologies

• The integration of liquid biopsy (LB) into routine clinical oncology has been hindered by a number of economic barriers, chief among them being high per-test costs and variable insurance coverage
• While LB offers advantages such as minimal invasiveness and real-time tumor monitoring, its financial burden—particularly in early detection and large-scale screening scenarios—continues to limit accessibility, scalability, and equitable adoption across healthcare systems. Multiple peer-reviewed studies and health system analyses underscore this growing concern
  • For Instances, In Feb 2025 Article by Journal of Experimental & Clinical Cancer Research high costs associated with LB tests and the potential lack of insurance coverage are a barrier to widespread adoption. The cost of LB ranges from USD 500 to USD 3,000 per test, depending on the complexity of the assay and the healthcare system. In comparison, imaging modalities such as CT scans and MRI scans can cost between USD300 and USD 5,000 with PET scans generally costing between USD 2,000 and USD 5,000. Tissue biopsies can range between USD 1,000 and USD 2,500 and cost is influenced by the type of biopsy and subsequent analysis

U.S. Liquid Biopsy Market Scope

The market is segmented on the basis of product, biomarker type, sample type, analytical type, application, clinical application, technology, end user and distribution channel.

• By Product

On the basis of product, the U.S. liquid biopsy market is segmented into consumables & accessories, instruments and services & software. In 2025, the consumables & accessories segment is expected to dominate the market with a market share of 50.95%. due to its high demand for routine testing, continuous replacement requirements, and essential role in ensuring accurate and reliable diagnostic results. The segment benefits from recurring purchases, widespread use in laboratories and hospitals, and growing adoption of advanced liquid biopsy technologies across clinical applications.

The consumables & accessories segment is expected to witness the fastest CAGR of 17.5% from 2025 to 2032. This growth is driven by their recurring use in routine diagnostic testing, constant replacement requirements, and essential role in ensuring the accuracy of liquid biopsy results. Consumables, such as assay kits, reagents, and collection tubes, are indispensable in both research and clinical workflows, making them a consistent revenue generator. Widespread adoption of liquid biopsy in oncology, coupled with rising demand for non-invasive testing methods, further boosts the segment’s dominance. Additionally, the integration of advanced technologies such as NGS and PCR-based platforms continues to expand the usage of consumables. Their recurring demand across hospitals, diagnostic laboratories, and reference centers ensures long-term growth, making consumables & accessories the backbone of the U.S. liquid biopsy market.

• By Biomarker Type

On the basis of biomarker type, the U.S. liquid biopsy market is segmented into circulating tumor cells (CTCs), circulating cell-free DNA (cfDNA), cell-free RNA, exosomes, extracellular vesicles, and others. In 2025, the circulating tumor cells (CTCs) segment is expected to dominate the market with a market share of 51.27% due to its crucial role in early cancer detection, real-time monitoring of tumor progression, and effectiveness in guiding personalized treatment strategies. Increasing clinical adoption, advancements in CTC isolation technologies, and growing preference for minimally invasive diagnostic methods further drive its market dominance.

Circulating Tumor Cells (CTCs) is expected to witness the fastest CAGR of 17.7% from 2025 to 2032. Their ability to provide real-time insights into cancer progression, metastasis, and therapeutic response has made them central to precision oncology. CTCs enable non-invasive sampling for early detection, recurrence monitoring, and treatment selection, offering significant clinical value. Technological advances in isolation and detection platforms are expanding their utility across multiple cancer types. Increasing research collaborations and clinical trials focusing on CTC-based diagnostics further strengthen their role in liquid biopsy applications. Hospitals, research institutions, and laboratories are adopting CTC-based testing as a critical diagnostic and monitoring tool. With the rising demand for personalized medicine and the growing importance of biomarker-driven therapies, CTCs are set to dominate the biomarker landscape in the U.S. liquid biopsy market.

• By Sample Type

On the basis of sample type, the U.S. liquid biopsy market is segmented into blood sample-based, urine sample-based, saliva fluid, cerebrospinal fluid (CSF), pleural fluid, tissue fluid, and others. In 2025, the blood sample-based segment is expected to dominate the market with a market share of 53.12% due to its minimally invasive nature, ease of collection, and wide clinical acceptance. It enables real-time monitoring of disease progression, supports early cancer detection, and facilitates personalized treatment decisions, driving higher adoption in hospitals, diagnostic centers, and research institutes.

The Blood Sample-Based segment is expected to witness the fastest CAGR of 17.9% from 2025 to 2032. Blood is the most widely adopted medium for liquid biopsy due to its minimally invasive collection method, cost-effectiveness, and ability to provide a comprehensive molecular profile. It allows the detection of circulating tumor DNA (ctDNA), CTCs, and exosomes with high sensitivity, making it suitable for early cancer detection, therapy monitoring, and recurrence tracking. Hospitals and diagnostic centers prefer blood-based liquid biopsies as they offer higher patient compliance and quick turnaround times compared to invasive tissue biopsies. Continuous advancements in sequencing technologies and assay platforms are enhancing accuracy and scalability. Moreover, its widespread acceptance across both clinical and research applications ensures that blood sample-based testing remains the preferred and dominant segment in the U.S. liquid biopsy market.

• By Analytical Type

On the basis of analytical type, the U.S. liquid biopsy market is segmented into molecular, proteomic, and histology/imaging. In 2025, the molecular segment is expected to dominate the market with a market share of 54.63% due to its high sensitivity and specificity in detecting genetic mutations and biomarkers. Its ability to enable early cancer diagnosis, guide targeted therapies, and monitor treatment response drives widespread adoption in clinical and research applications.

The Molecular Analysis segment is expected to witness the fastest CAGR of 17.4% from 2025 to 2032. This segment dominates due to its capability to analyze genetic mutations, alterations, and biomarkers such as cfDNA and CTCs with precision. Molecular assays are essential for detecting actionable targets in oncology, enabling clinicians to tailor treatments for individual patients. Techniques such as PCR, next-generation sequencing, and digital droplet PCR are widely integrated into clinical workflows, boosting demand. The rise of precision medicine and biomarker-driven therapies further enhances the reliance on molecular analysis. In addition, the growing use of liquid biopsy for therapy selection, treatment monitoring, and recurrence detection ensures consistent adoption. Strong research funding and regulatory approvals for molecular-based liquid biopsy kits reinforce its leadership, making molecular analysis the backbone of diagnostic and clinical decision-making in the U.S. market.

• By Application

On the basis of application, the U.S. liquid biopsy market is segmented into cancer applications and non-cancer applications. In 2025, the cancer applications segment is expected to dominate the market with a market share of 76.77% due to the increasing prevalence of cancer worldwide, growing demand for early and accurate diagnosis, and the adoption of liquid biopsy technologies for therapy selection, treatment monitoring, and recurrence detection.

Cancer Applications is expected to witness the fastest CAGR of 17.2% from 2025 to 2032. Liquid biopsy has emerged as a transformative tool for early cancer detection, therapy selection, and disease monitoring, offering non-invasive alternatives to surgical tissue biopsies. Cancer-focused applications benefit from growing adoption in oncology clinics and hospitals, where they enable real-time tracking of tumor evolution and treatment effectiveness. Rising cancer prevalence in the U.S. and increasing demand for personalized therapies have further fueled this segment’s expansion. Advanced technologies such as NGS and PCR-based assays allow comprehensive genomic profiling, supporting targeted therapy decisions. Moreover, the need for monitoring minimal residual disease (MRD) and detecting recurrence strengthens the role of liquid biopsy in oncology. As precision medicine advances, cancer applications remain the primary driver of growth in the liquid biopsy landscape.

• By Clinical Application

On the basis of clinical application, the U.S. liquid biopsy market is segmented into routine screening, therapy selection, treatment monitoring, recurrence monitoring, patient work-up, and others. In 2025, the routine screening segment is expected to dominate the market with a market share of 39.74% due to the rising focus on early cancer detection, increasing awareness of preventive healthcare, and the growing adoption of liquid biopsy tests in hospitals and diagnostic centers for regular patient monitoring.

Routine Screening is expected to witness the fastest CAGR of 19.5% from 2025 to 2032, the highest across all categories. The growing emphasis on early disease detection, particularly in oncology, is fueling demand for liquid biopsy in population-wide screening programs. Routine screening leverages non-invasive testing to identify cancers at earlier, more treatable stages, improving patient outcomes while reducing healthcare costs. Technological innovations in cfDNA analysis and high-throughput sequencing platforms have enhanced the accuracy and scalability of screening programs. Increasing adoption by hospitals, reference laboratories, and diagnostic centers highlights the segment’s clinical relevance. Furthermore, the growing shift toward preventive healthcare, coupled with favorable regulatory support for novel diagnostic tools, strengthens adoption. Routine screening thus plays a crucial role in expanding liquid biopsy from specialized oncology practices into broader healthcare settings across the U.S.

• By Technology

On the basis of technology, the U.S. liquid biopsy market is segmented into next-generation sequencing (NGS), polymerase chain reaction (PCR)-based, immunoassays & mass spectrometry, microfluidics-based, nanotechnology, and microarrays. In 2025, the next-generation sequencing (NGS) segment is expected to dominate the market with a market share of 45.05% due to its high accuracy, ability to detect multiple genetic mutations simultaneously, and growing adoption in precision oncology for early diagnosis, therapy selection, and treatment monitoring.

Nanotechnology is projected to be the fastest growing technology segment, recording a CAGR of 17.3% during the forecast period. Nanotechnology offers advanced solutions for isolating, detecting, and analyzing biomarkers such as CTCs, exosomes, and cfDNA with high sensitivity and specificity. Its application enhances liquid biopsy platforms by enabling the detection of ultra-low concentrations of tumor-derived material, facilitating earlier diagnosis and better monitoring of cancer progression. Research-driven innovations in nanoparticle-based assays, microfluidic devices, and biosensors are accelerating clinical adoption. Hospitals and laboratories are increasingly investing in nanotechnology-enabled solutions due to their precision and scalability. Moreover, its role in enabling point-of-care diagnostics and integration with other platforms like NGS ensures long-term growth. As liquid biopsy continues to evolve toward more accurate and less invasive solutions, nanotechnology stands out as a transformative enabler of next-generation diagnostics.

• By End User

On the basis of end user, the U.S. liquid biopsy market is segmented into hospitals, reference laboratories, diagnostics centers, research centres and academic institutes, clinics, and others. In 2025, the hospitals segment is expected to dominate the market with a market share of 52.83% due to increasing emphasis on early cancer detection, growing awareness of preventive healthcare, and widespread adoption of liquid biopsy tests in hospitals, diagnostic centers, and research institutes for regular patient monitoring.

Hospitals is expected to witness the fastest CAGR of 17.5% from 2025 to 2032. Hospitals are the primary centers for cancer diagnosis, treatment monitoring, and therapy selection, making them central to liquid biopsy adoption. The growing integration of advanced diagnostic tools in hospital settings supports efficient decision-making and patient management. Hospitals also play a key role in routine screening programs and post-treatment recurrence monitoring, ensuring steady demand. Their ability to handle large patient volumes, coupled with investments in state-of-the-art laboratories and partnerships with diagnostic companies, enhances accessibility to liquid biopsy tests. Moreover, hospitals benefit from insurance reimbursements and government initiatives promoting non-invasive cancer diagnostics. As liquid biopsy technologies become more mainstream, hospitals are expected to remain the dominant end-user, driving adoption across both urban and regional healthcare systems in the U.S.

• By Distribution Channel

On the basis of distribution channel, the U.S. liquid biopsy market is segmented into direct tender, third party distributor, and others. In 2025, the direct tender segment is expected to dominate the market with a market share of 65.18% due to bulk procurement by hospitals and healthcare institutions, cost-effectiveness, long-term supply agreements, and streamlined purchasing processes that ensure consistent availability of liquid biopsy products.

The Direct Tender distribution channel is expected to be the fastest growing, with a CAGR of 17.3% during the forecast period. Direct tendering ensures bulk procurement of liquid biopsy kits, consumables, and instruments, primarily by hospitals, reference laboratories, and large diagnostic networks. This model supports cost efficiency and strengthens supplier–buyer relationships, offering long-term contracts and stable revenue streams for manufacturers. The increasing preference for direct procurement is also driven by the need to ensure consistent product availability, particularly for high-volume routine testing and cancer diagnostics. Additionally, direct tenders facilitate better pricing transparency and allow hospitals to negotiate value-based agreements with suppliers. With rising demand for advanced consumables and diagnostic platforms, direct tendering is becoming a preferred channel across large healthcare facilities. This trend reinforces its role as a crucial distribution strategy in the U.S. liquid biopsy market.

U.S. Liquid Biopsy Market Share

The U.S. liquid biopsy market is primarily led by well-established companies, including:

• Guardant Health (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Exact Sciences Corporation (Genomic Health) (U.S.)
• Quest Diagnostics Incorporated (U.S.)
• Natera, Inc. (U.S.)
• NeoGenomics Laboratories (U.S.)
• Tempus AI, Inc. (U.S.)
• Eurofins Genomics (Luxembourg)
• Veracyte, Inc. (U.S.)
• Labcorp (U.S.)
• Invitae Corporation (U.S.)
• Caris Life Sciences (U.S.)
• mdxhealth (Belgium)
• Predicine (U.S.)
• ANGLE plc (United Kingdom)
• Oncocyte Corporation (U.S.)

Latest Developments in U.S. Liquid Biopsy Market

• In August 2025, Mass General Brigham announced two clinical trials using Quest Diagnostics’ Haystack MRD ctDNA test to guide post-surgical treatment in cutaneous squamous cell carcinoma and HPV-independent head and neck cancer. The trials aim to demonstrate the test’s ability to detect relapse months earlier than imaging, enabling more timely and tailored treatment decisions. For Quest, this advancement strengthens clinical adoption of its ctDNA platform and reinforces its position in advancing precision oncology solutions
• In August 2025, Quest Diagnostics completed the acquisition of select clinical testing assets from Fresenius Medical Care’s Spectra Laboratories, a leader in renal-specific testing. The deal strengthens Quest’s ability to deliver dialysis-related clinical testing to independent dialysis clinics across the U.S. Additionally, Quest plans to acquire select dialysis-related water testing assets by the end of 2025, further enhancing its specialized renal testing capabilities
• In July 2024, Quest Diagnostics announced the introduction of HPV specimen self-collection for cervical cancer screening. This development enables women to collect their own samples in a clinical setting, improving access and convenience for cervical cancer screening. The initiative supports early detection and prevention, particularly for underserved populations who may face barriers to traditional screening methods
• In August 2025, Natera launched Fetal Focus as a new non-invasive prenatal test (NIPT) for inherited single-gene conditions. This product launch, supported by the EXPAND trial showing 91% sensitivity, enables fetal testing even when the biological father is unavailable, addressing a key diagnostic gap. It strengthens Natera’s women’s health portfolio, leverages its LinkedSNP technology for diverse populations, and boosts its market leadership in cfDNA-based prenatal testing while contributing to revenue growth and strategic expansion
• In April 2025, Natera began a broad clinical rollout of its Signatera Genome—an ultra-sensitive, personalized MRD assay for ctDNA detection using mPCR-NGS, capable of spotting tumor DNA at levels as low as 1 part per million. The launch is backed by a large-scale pan-cancer validation encompassing over 3,000 plasma samples, where the assay detected recurrence well before clinical signs appeared Natera. Offered in CLIA, IUO, and RUO formats, Signatera Genome enhances patient management through earlier relapse detection and improved surveillance across cancers like breast, colorectal, lung, melanoma, and renal cell carcinoma

SKU-74610